Search details
1.
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Int J Cancer
; 154(6): 1043-1056, 2024 Mar 15.
Article
in English
| MEDLINE | ID: mdl-37994647
2.
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.
Liver Int
; 44(5): 1108-1125, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38517286
3.
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab.
Oncology
; 101(5): 283-291, 2023.
Article
in English
| MEDLINE | ID: mdl-36657420
4.
Survey on Multi-Objective Task Allocation Algorithms for IoT Networks.
Sensors (Basel)
; 23(1)2022 Dec 23.
Article
in English
| MEDLINE | ID: mdl-36616751
5.
Protein Kinase D1, Reduced in Human Pancreatic Tumors, Increases Secretion of Small Extracellular Vesicles From Cancer Cells That Promote Metastasis to Lung in Mice.
Gastroenterology
; 159(3): 1019-1035.e22, 2020 09.
Article
in English
| MEDLINE | ID: mdl-32446697
6.
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma.
Target Oncol
; 19(1): 29-39, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-38252195
7.
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab.
Target Oncol
; 2024 Apr 30.
Article
in English
| MEDLINE | ID: mdl-38689194
8.
Treatment of Non-Anastomotic Biliary Strictures after Liver Transplantation: How Effective Is Our Current Treatment Strategy?
J Clin Med
; 12(10)2023 May 16.
Article
in English
| MEDLINE | ID: mdl-37240598
9.
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population.
Eur J Cancer
; 180: 9-20, 2023 02.
Article
in English
| MEDLINE | ID: mdl-36527976
10.
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study.
J Cancer Res Clin Oncol
; 149(9): 5591-5602, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-36509984
11.
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients.
J Cancer Res Clin Oncol
; 149(10): 7565-7577, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-36976353
12.
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
Target Oncol
; 18(2): 221-233, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36920648
13.
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients.
Eur J Cancer
; 189: 112933, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37385069
Results
1 -
13
de 13
1
Next >
>>